Literature DB >> 11684822

Preventive effects of Bifidobacterium- and Lactobacillus-fermented milk on the development of inflammatory bowel disease in senescence-accelerated mouse P1/Yit strain mice.

S Matsumoto1, N Watanabe, A Imaoka, Y Okabe.   

Abstract

BACKGROUND/AIMS: We recently discovered inflammatory bowel disease (IBD) in the ileum and cecum of SAMP1/Yit strain mice under specific pathogen-free (SPF) conditions. To determine the effect of lactic acid bacteria (LAB - Bifidobacterium breve, Bifidobacterium bifidum and Lactobacillus acidophilus)-fermented milk on the prevention of IBD in SAMP1/Yit strain mice, we compared the disease severity on the intestinal inflammation among the group of mice fed saline, unfermented milk or LAB-fermented milk.
METHODS: Three-week-old SAMP1/Yit strain mice (n = 72) were subdivided into three groups, that were fed saline, unfermented milk and LAB-fermented milk, respectively. The diets were orally administered daily via a gastric tube. When the mice reached 20 weeks of age, they were sacrificed and the IBD scores were compared among the three groups.
RESULTS: Administration of the LAB-fermented milk to SAMP1/Yit strain mice reduced histological injury score, compared with those in saline-treated or unfermented milk-treated SAMP1/Yit strain mice. Ileal tissue weight and myeloperoxidase activity also reduced by treatment of LAB-fermented milk. Moreover, the tissue contents of immunoglobulins such as IgG1 and IgG2a were lower in the inflammatory regions in the SAMP1/Yit strain group fed LAB-fermented milk than that fed saline and unfermented milk. Cytokine-specific ELISA assays indicated the production of T-helper 1 cytokines such as interferon-gamma and tumor necrosis factor-alpha in the culture supernatants of MLN cells in the SAMP1/Yit strain group fed LAB-fermented milk was lower than those fed saline and unfermented milk. On the contrary, the production of interleukin-10 in MLN cells increased by prevention with LAB-fermented milk.
CONCLUSION: LAB-fermented milk is beneficial for the treatment of murine IBD and this effect may be modulated through stabilization of the mucosal immunity by LAB. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684822     DOI: 10.1159/000048846

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  20 in total

1.  In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1.

Authors:  K Matsuzaki; Y Tsuzuki; H Matsunaga; T Inoue; J Miyazaki; R Hokari; Y Okada; A Kawaguchi; S Nagao; K Itoh; S Matsumoto; S Miura
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

Review 2.  Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease.

Authors:  Akira Andoh; Yoshihide Fujiyama
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 3.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

4.  Rationale for Using of Bifidobacterium Probiotic Strains-Fermented Milk Against Colitis Based on Animal Experiments and Clinical Trials.

Authors:  Akemi Imaoka; Yoshinori Umesaki
Journal:  Probiotics Antimicrob Proteins       Date:  2008-12-25       Impact factor: 4.609

5.  Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells.

Authors:  S Matsumoto; T Hara; T Hori; K Mitsuyama; M Nagaoka; N Tomiyasu; A Suzuki; M Sata
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

Review 6.  SAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis.

Authors:  Theresa T Pizarro; Luca Pastorelli; Giorgos Bamias; Rekha R Garg; Brian K Reuter; Joseph R Mercado; Marcello Chieppa; Kristen O Arseneau; Klaus Ley; Fabio Cominelli
Journal:  Inflamm Bowel Dis       Date:  2011-05-06       Impact factor: 5.325

7.  Fucoidan derived from Cladosiphon okamuranus Tokida ameliorates murine chronic colitis through the down-regulation of interleukin-6 production on colonic epithelial cells.

Authors:  S Matsumoto; M Nagaoka; T Hara; I Kimura-Takagi; K Mistuyama; S Ueyama
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

8.  Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells.

Authors:  Akemi Imaoka; Tatsuichiro Shima; Kimitoshi Kato; Shigeaki Mizuno; Toshiki Uehara; Satoshi Matsumoto; Hiromi Setoyama; Taeko Hara; Yoshinori Umesaki
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 9.  Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease.

Authors:  Rok Orel; Tina Kamhi Trop
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

10.  A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer.

Authors:  S Matsumoto; T Hara; M Nagaoka; A Mike; K Mitsuyama; T Sako; M Yamamoto; S Kado; T Takada
Journal:  Immunology       Date:  2008-10-15       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.